Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors

Sujin Lee, Hideo Yagita, Thomas J. Sayers, Esteban Celis

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

TNF-related apoptosis-inducing ligand (TRAIL) is a member of the TNF family of cytokines, which can induce apoptosis in various tumor cells by engaging the receptors, DR4 and DR5. Bortezomib (Velcade) is a proteasome inhibitor that has been approved for patients with multiple myeloma. There is some experimental evidence in preclinical models that bortezomib can enhance the susceptibility of tumors to TRAIL-induced apoptosis. In this study, we investigated the effects of TRAIL-induced death using an agonistic antibody to the TRAIL receptor DR5 (α-DR5) in combination with bortezomib administered to mice previously injected with breast cancer cells (TUBO). This combination had some beneficial therapeutic effect, which was significantly enhanced by the co-administration of a Toll-like receptor 9 agonist (CpG). In contrast, single agent treatments had little effect on tumor growth. In addition, we evaluated the effect of combination with α-DR5, bortezomib, and CpG in the prevention/treatment of spontaneous mammary tumors in Balb-neuT mice. In this model, which is more difficult to treat, we observed dramatic antitumor effects of α-DR5, bortezomib and CpG combination therapy. Since such a mouse model more accurately reflects the immunological tolerance that exists in human cancer, our results strongly suggest that these combination strategies could be directly applied to the therapy for cancer patients.

Original languageEnglish (US)
Pages (from-to)1073-1081
Number of pages9
JournalCancer Immunology, Immunotherapy
Volume59
Issue number7
DOIs
StatePublished - Jul 1 2010
Externally publishedYes

Fingerprint

TNF-Related Apoptosis-Inducing Ligand
TNF-Related Apoptosis-Inducing Ligand Receptors
Breast Neoplasms
Neoplasms
Therapeutics
Toll-Like Receptor 9
Apoptosis
Proteasome Inhibitors
Therapeutic Uses
Multiple Myeloma
Bortezomib
Cytokines
Antibodies
Growth

Keywords

  • Balb-neuT mice
  • Bortezomib
  • Breast tumors
  • CpG
  • α-DR5

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Cite this

Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors. / Lee, Sujin; Yagita, Hideo; Sayers, Thomas J.; Celis, Esteban.

In: Cancer Immunology, Immunotherapy, Vol. 59, No. 7, 01.07.2010, p. 1073-1081.

Research output: Contribution to journalArticle

@article{a47a4f35068145e3beecddd0b729c491,
title = "Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors",
abstract = "TNF-related apoptosis-inducing ligand (TRAIL) is a member of the TNF family of cytokines, which can induce apoptosis in various tumor cells by engaging the receptors, DR4 and DR5. Bortezomib (Velcade) is a proteasome inhibitor that has been approved for patients with multiple myeloma. There is some experimental evidence in preclinical models that bortezomib can enhance the susceptibility of tumors to TRAIL-induced apoptosis. In this study, we investigated the effects of TRAIL-induced death using an agonistic antibody to the TRAIL receptor DR5 (α-DR5) in combination with bortezomib administered to mice previously injected with breast cancer cells (TUBO). This combination had some beneficial therapeutic effect, which was significantly enhanced by the co-administration of a Toll-like receptor 9 agonist (CpG). In contrast, single agent treatments had little effect on tumor growth. In addition, we evaluated the effect of combination with α-DR5, bortezomib, and CpG in the prevention/treatment of spontaneous mammary tumors in Balb-neuT mice. In this model, which is more difficult to treat, we observed dramatic antitumor effects of α-DR5, bortezomib and CpG combination therapy. Since such a mouse model more accurately reflects the immunological tolerance that exists in human cancer, our results strongly suggest that these combination strategies could be directly applied to the therapy for cancer patients.",
keywords = "Balb-neuT mice, Bortezomib, Breast tumors, CpG, α-DR5",
author = "Sujin Lee and Hideo Yagita and Sayers, {Thomas J.} and Esteban Celis",
year = "2010",
month = "7",
day = "1",
doi = "10.1007/s00262-010-0834-0",
language = "English (US)",
volume = "59",
pages = "1073--1081",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "7",

}

TY - JOUR

T1 - Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors

AU - Lee, Sujin

AU - Yagita, Hideo

AU - Sayers, Thomas J.

AU - Celis, Esteban

PY - 2010/7/1

Y1 - 2010/7/1

N2 - TNF-related apoptosis-inducing ligand (TRAIL) is a member of the TNF family of cytokines, which can induce apoptosis in various tumor cells by engaging the receptors, DR4 and DR5. Bortezomib (Velcade) is a proteasome inhibitor that has been approved for patients with multiple myeloma. There is some experimental evidence in preclinical models that bortezomib can enhance the susceptibility of tumors to TRAIL-induced apoptosis. In this study, we investigated the effects of TRAIL-induced death using an agonistic antibody to the TRAIL receptor DR5 (α-DR5) in combination with bortezomib administered to mice previously injected with breast cancer cells (TUBO). This combination had some beneficial therapeutic effect, which was significantly enhanced by the co-administration of a Toll-like receptor 9 agonist (CpG). In contrast, single agent treatments had little effect on tumor growth. In addition, we evaluated the effect of combination with α-DR5, bortezomib, and CpG in the prevention/treatment of spontaneous mammary tumors in Balb-neuT mice. In this model, which is more difficult to treat, we observed dramatic antitumor effects of α-DR5, bortezomib and CpG combination therapy. Since such a mouse model more accurately reflects the immunological tolerance that exists in human cancer, our results strongly suggest that these combination strategies could be directly applied to the therapy for cancer patients.

AB - TNF-related apoptosis-inducing ligand (TRAIL) is a member of the TNF family of cytokines, which can induce apoptosis in various tumor cells by engaging the receptors, DR4 and DR5. Bortezomib (Velcade) is a proteasome inhibitor that has been approved for patients with multiple myeloma. There is some experimental evidence in preclinical models that bortezomib can enhance the susceptibility of tumors to TRAIL-induced apoptosis. In this study, we investigated the effects of TRAIL-induced death using an agonistic antibody to the TRAIL receptor DR5 (α-DR5) in combination with bortezomib administered to mice previously injected with breast cancer cells (TUBO). This combination had some beneficial therapeutic effect, which was significantly enhanced by the co-administration of a Toll-like receptor 9 agonist (CpG). In contrast, single agent treatments had little effect on tumor growth. In addition, we evaluated the effect of combination with α-DR5, bortezomib, and CpG in the prevention/treatment of spontaneous mammary tumors in Balb-neuT mice. In this model, which is more difficult to treat, we observed dramatic antitumor effects of α-DR5, bortezomib and CpG combination therapy. Since such a mouse model more accurately reflects the immunological tolerance that exists in human cancer, our results strongly suggest that these combination strategies could be directly applied to the therapy for cancer patients.

KW - Balb-neuT mice

KW - Bortezomib

KW - Breast tumors

KW - CpG

KW - α-DR5

UR - http://www.scopus.com/inward/record.url?scp=77953071740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953071740&partnerID=8YFLogxK

U2 - 10.1007/s00262-010-0834-0

DO - 10.1007/s00262-010-0834-0

M3 - Article

C2 - 20213120

AN - SCOPUS:77953071740

VL - 59

SP - 1073

EP - 1081

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 7

ER -